CJC-1295 official-source update · version 1
This page preserves this version’s findings and source pins. Open the current profile →
Official-source update
Reviewed 2026-09-19 · Preserved version 1
The tested substance may not match every marketed name
FDA’s December 2024 briefing considered several CJC-1295 and DAC forms separately. The limited clinical reports appeared to involve a DAC active moiety with incompletely specified form; other nominated forms lacked equivalent clinical information. FDA PDF pp. 46, 50 ↗
More findings and the sources behind them
Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision.
Hormone changes in healthy adults did not establish treatment benefit
The reviewed reports involved healthy adults, not patients with growth-hormone deficiency, and did not measure key clinical outcomes such as body-composition change or height velocity. FDA did not consider them evidence of effectiveness for that condition. FDA PDF pp. 50 ↗
The safety sample was small and mostly short exposure
FDA described 63 exposed participants, predominantly men, with most receiving a single exposure. That evidence did not characterize long-term safety or pediatric use. FDA PDF pp. 46 ↗
Adverse events need careful attribution
The briefing describes injection-site and systemic reactions, including heart-rate and blood-pressure effects. It also discusses a death attributed to coronary disease in an unpublished trial account; the document does not prove CJC-1295 caused that death. FDA PDF pp. 46 ↗
What remains to be checked
- Check subsequent advisory records and any final FDA action separately from the staff briefing.
- Retrieve and appraise the original human reports and proposed formulation or route; agency search findings are dated and do not establish a complete worldwide literature review.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
FDA cjc-1295 briefing for the December 2024 advisory meeting ↗
Source dated 2024-12-04; retrieved 2026-09-19.
- The tested substance may not match every marketed name · PDF pp. 46, 50 of 72
- Hormone changes in healthy adults did not establish treatment benefit · PDF pp. 50 of 72
- The safety sample was small and mostly short exposure · PDF pp. 46 of 72
- Adverse events need careful attribution · PDF pp. 46 of 72
SHA-256:
202fa022933ef27241c6e19f2156ca764854ccf4a7286e0fe1f1b6b56df39506